Shares of Moderna (NASDAQ: MRNA) plunged in pre-market trading on Thursday as the messenger RNA (mRNA) biotechnology company's Q3 earnings missed estimates. The company posted revenues of $3.4 billion, a drop of 32% year-over-year, missing Street estimates by $170 million. The fall in revenues was mainly due to a decline in sales of its COVID-19 vaccines. Diluted earnings came in at $2.53 per share, a drop of 67%, again falling short of analysts' estimates of $3.3. Stéphane Bancel, Moderna's CEO stated, "Today's earnings continue to show strong corporate momentum. With $13.
https://www.tipranks.com/news/moderna-crashes-as-q3-results-disappoint?utm_source=advfn.com&utm_medium=referral
Moderna (NASDAQ:MRNA)
Historical Stock Chart
From Dec 2022 to Jan 2023 Click Here for more Moderna Charts.
Moderna (NASDAQ:MRNA)
Historical Stock Chart
From Jan 2022 to Jan 2023 Click Here for more Moderna Charts.